[go: up one dir, main page]

MX2023012971A - Agonistas del receptor de orexina y sus usos. - Google Patents

Agonistas del receptor de orexina y sus usos.

Info

Publication number
MX2023012971A
MX2023012971A MX2023012971A MX2023012971A MX2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A
Authority
MX
Mexico
Prior art keywords
sub
receptor agonists
orexin receptor
formula
pharmaceutically acceptable
Prior art date
Application number
MX2023012971A
Other languages
English (en)
Inventor
Gilles Ouvry
Claudia Beato
Prafulkumar Chovatia
Davide Marinelli
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2023012971A publication Critical patent/MX2023012971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se proporcionan compuestos con la Fórmula (I), o una sal farmacéuticamente aceptable de estos, en donde n, m, A1, A2, A3, A4, A5, A6, L1, L2, R1, R2, R3, Y y Z se definen en la presente. En la presente también se proporcionan composiciones farmacéuticas que comprenden un compuesto con la Fórmula (I) o una sal farmacéuticamente aceptable de este, y métodos para el uso de un compuesto con la Fórmula (I) o una sal farmacéuticamente aceptable de este, por ejemplo, en el tratamiento de una enfermedad o un trastorno que puede tratarse mediante la administración de un agonista de orexina.(ver fórmula).
MX2023012971A 2021-05-03 2022-05-03 Agonistas del receptor de orexina y sus usos. MX2023012971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183321P 2021-05-03 2021-05-03
PCT/EP2022/061851 WO2022233872A1 (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012971A true MX2023012971A (es) 2024-01-16

Family

ID=81940742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012971A MX2023012971A (es) 2021-05-03 2022-05-03 Agonistas del receptor de orexina y sus usos.

Country Status (12)

Country Link
US (1) US20240254143A1 (es)
EP (1) EP4334323A1 (es)
JP (1) JP2024516033A (es)
KR (1) KR20240004802A (es)
CN (1) CN117616030A (es)
AU (1) AU2022269811A1 (es)
BR (1) BR112023022050A2 (es)
CA (1) CA3217403A1 (es)
IL (1) IL308099A (es)
MX (1) MX2023012971A (es)
TW (1) TW202309051A (es)
WO (1) WO2022233872A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US20240425519A1 (en) * 2021-11-04 2024-12-26 University Of Washington Novel spirocyclic compounds as klhdc2 ligands
TW202444724A (zh) 2023-01-31 2024-11-16 愛爾蘭商爵士製藥愛爾蘭有限責任公司 大環食慾激素受體促效劑及其用途
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
ES2459496T3 (es) * 2009-12-21 2014-05-09 Novartis Ag Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
PL3984994T3 (pl) * 2016-02-04 2024-11-04 Takeda Pharmaceutical Company Limited Podstawiony związek piperydyny jako agonista oreksyny typu 2 do leczenia narkolepsji
EP3816153B1 (en) * 2018-06-29 2023-10-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3924058B1 (en) * 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
IL308099A (en) 2023-12-01
TW202309051A (zh) 2023-03-01
JP2024516033A (ja) 2024-04-11
CA3217403A1 (en) 2022-11-10
BR112023022050A2 (pt) 2023-12-26
AU2022269811A1 (en) 2023-11-16
KR20240004802A (ko) 2024-01-11
US20240254143A1 (en) 2024-08-01
CN117616030A (zh) 2024-02-27
WO2022233872A1 (en) 2022-11-10
EP4334323A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
MX2023015074A (es) Agonistas de sulfonamidas del receptor de orexina y sus usos.
EP4458834A3 (en) Heterocyclic glp-1 agonists
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
CR20230066A (es) Agonistas del glp-1 heterocíclicos
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2025004220A (es) Compuestos triciclicos y sus usos
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2020000268A (es) Agonista de fxr.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2025005223A (es) Agonistas del estimulador de genes de interferon (sting)
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2024014790A (es) Agonistas del receptor macrocíclico de orexina y sus usos
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
DK1781299T3 (da) Anti-inflammatoriske midler
PH12022550859A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
MX2025008851A (es) Agonistas del receptor macrociclico de orexina y sus usos